Former Abusers of Anabolic Androgenic Steroids Exhibit Decreased Testosterone Levels and Hypogonadal Symptoms Years after Cessation: A Case-Control Study by Jon Jarløv Rasmussen (2993427)

“…</p><p>Methods</p><p>This study had a cross-sectional case-control design and involved 37 current AAS abusers, 33 former AAS abusers (mean (95%CI) elapsed duration since AAS cessation: 2.5 (1.7; 3.7) years) and 30 healthy control participants. …”

Annual treatment frequencies in recurrence and non-recurrence groups. by Yasuyuki Sotani (20114144)

“…Mean outpatient visits in the recurrence group decreased from 13.6 ± 3.0 to 11.9 ± 5.0, 8.1 ± 3.9, and 7.8 ± 3.2 at 1, 2, and 3 years postoperatively, respectively (Kruskal-Wallis test, p < 0.001). …”

Annual number of outpatient visits in all eyes. by Yasuyuki Sotani (20114144)

“…<p>Mean visit frequency (mean ± standard deviation) significantly decreased from 11.5 ± 4.3 preoperatively to 8.8 ± 4.1, 5.0 ± 3.4, and 4.4 ± 3.2 visits in the first, second, and third postoperative years, respectively (Kruskal–Wallis test, P < 0.001; Dunn’s test, **P < 0.01). …”

Decrease in Total Cholesterol level based on Salt Intake. by Giti Azim (20940548)

Decrease in Blood Glucose level based on Education Level. by Giti Azim (20940548)

Annual treatment frequencies in all eyes. by Yasuyuki Sotani (20114144)

“…Outpatient visit frequency also significantly declined from 11.5 ± 4.3 visits in the year before surgery to 8.8 ± 4.1, 5.0 ± 3.4, and 4.4 ± 3.2 visits in the first, second, and third postoperative years, respectively (Kruskal-Wallis test, p < 0.001; <a href="http://www.plosone.org/article/info:doi/10.1371/journal.pone.0332941#pone.0332941.g004" target="_blank">Fig 4</a>).…”

Annual number of outpatient visits in recurrence and non-recurrence groups. by Yasuyuki Sotani (20114144)

“…<p>In the recurrence group, mean outpatient visits (± standard deviation) decreased from 13.6 ± 3.0 to 11.9 ± 5.0, 8.1 ± 3.9, and 7.8 ± 3.2 at 1, 2, and 3 years postoperatively, respectively (Kruskal-Wallis test, P < 0.001; Dunn’s test, **P < 0.01). …”

Fig 5 - by Ina Jahreis (11752073)

Dimerization of [Fe^III(bpy)₃]³⁺ in Aqueous Solutions: Elucidating a Mechanism Based on Historical Proposals, Electrochemical Data, and Computationa... by Nicolas E. Holubowitch (9254254)

Subjects:

Representative examples of LBNP and LBPP/hypoxia experiment. by Marcus Thudium (6441863)

The average speed of the model (step length/step duration), <i>v</i>, vs. the phase of a perturbation pulse, <i>φ</i> for a pulse of constant amplitude and duration. by Jooeun Ahn (299192)

Procedure related data, LBNP, LBPP and hypoxia. by Marcus Thudium (6441863)

“…Decreasing levels of LBNP were applied in 5-minute steps until subjects reached presyncope. …”

Individual biometric data of patients. by Marcus Thudium (6441863)

“…Decreasing levels of LBNP were applied in 5-minute steps until subjects reached presyncope. …”

Structure of P-YOLOv5s-GRNF. by Zhongjian Xie (4633099)

Pharmacologically induced torpor by 5′-AMP does not decrease platelet count despite decreased body temperature. by Edwin L. de Vrij (550179)

“…<p>A) Pharmacologically induced torpor by 5′-AMP in mice does not decrease platelet count during torpor and shows an increase upon arousal. …”

KOR-agonist (U50'488) and MOR-agonist (DAMGO) decrease symptoms in OVA-allergic mice. by Swantje C. Duncker (154707)

Fig 5 - by Jacob C. Jentzer (4746999)

Mean and standard deviation of vascular density. by Beatriz Cordon (9745619)

Mean and standard deviation of vascular density. by Beatriz Cordon (9745619)

Mean and standard deviation of vascular density. by Beatriz Cordon (9745619)